https://www.selleckchem.com/pr....oducts/pexidartinib-
54 ± 0.18 ng/mm2vs. 0.10 ± 0.03 ng/mm2, after application of a hydrogel in finite conditions. Canrenone, an active metabolite of SPL, was also quantified in skin samples. In addition to being used for the treatment of delayed cutaneous wound healing by site-specific antagonism of the MR, the formulation might also be used to treat pilosebaceous androgen-related skin diseases, e.g. acne vulgaris, since SPL is a potent androgen receptor antagonist. Paclitaxel (PTX)-coated peripheral arterial devices have been shown to decreas
Curtir
Comentario
Compartilhar
